Who is sponsoring NCT01232504?

NCT01232504 is sponsored by Xiamen Amoytop Biotech Co., Ltd..

What drugs are being tested in NCT01232504?

Interventions: rhGM-CSF group, rhG-CSF+rhGM-CSF group, rhG-CSF group.

What is the status of NCT01232504?

NCT01232504 is currently COMPLETED.

Last reviewed 2014-10-27 · How we verify

Effect of Granulocyte-macrophage Stimulating Factor on Prevention and Treatment of Invasive Fungal Diseases in the Recipients of Allogeneic Stem Cell Transplantation: A Prospective Multicenter Randomized Phase 4 Trial

NCT01232504 Phase 4 COMPLETED Results posted

We conducted a prospective, multicenter, open-label randomized trial to compare the antifungal effect of Recombinant Human Granulocyte-macrophage Stimulating Factor (rhGM-CSF), Recombinant Human Granulocyte Stimulating Factor (rhG-CSF) or a combination of rhGM-CSF and rhG-CSF for neutropenic patients undergoing allogeneic stem cell transplantation.

Details

Lead sponsor	Xiamen Amoytop Biotech Co., Ltd.
Phase	Phase 4
Status	COMPLETED
Enrolment	206
Start date	2009-09
Completion	2013-06

Conditions

Mycoses

Interventions

rhGM-CSF group
rhG-CSF+rhGM-CSF group
rhG-CSF group

Primary outcomes

Incidences of Invasive Fungal Diseases (IFD) — 100 day post transplant
The incidence of proven and probable Invasive fungal diseases (IFD) within 100 days post transplantation

Countries

China